Free Newsletter
Good news: Merck to add 310 jobs; bad news: Biovail/Valeant to cut 1,100
It promised North Carolina 440 jobs in two years to meet increased demand for its vaccines. Merck now says it will add 310 more. "We have grown much faster than anyone had anticipated," says plant manager John Wagner. Separately, the drug giant says it is delaying the closure of some Dutch operations while it sorts out alternatives for employees. Both the U.S. and Canada will suffer job losses thanks to synergies identified in the Biovail acquisition of Valeant. The combined 4,400-employee workforce is expected to be trimmed by 25 percent. Report | Article | Article
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: